Actively Recruiting
Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-11-28
400
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to learn how well urinary proteins can predict treatment response in patients with locally advanced colorectal cancer (LACC) undergoing neoadjuvant therapy. The main question it aims to answer is: Can urinary protein markers help predict and evaluate how patients with LACC respond to neoadjuvant therapy? Participants diagnosed with LACC will provide urine samples before and after neoadjuvant therapy. These samples will be analyzed using 4D deep urinary proteomics and machine learning to identify proteins linked to treatment response. Some participants' tumor tissues will also be used to create organoid models for further testing.
CONDITIONS
Official Title
Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18-75 years
- Pathologically confirmed diagnosis of locally advanced colorectal cancer (cT3-4 and/or N+)
- Planned to undergo neoadjuvant therapy followed by surgical resection
- No evidence of distant metastasis (M0) confirmed by imaging (CT and/or PET-CT)
- Clinically assessed as able to tolerate and complete full neoadjuvant treatment
- No prior anti-tumor therapy before treatment start
- Willing and able to provide urine samples as required
- Written informed consent obtained
You will not qualify if you...
- History of or current other malignancies
- Severe hepatic, renal, cardiovascular, or metabolic diseases affecting urinary protein metabolism
- Recent use of medications affecting protein metabolism (e.g., glucocorticoids, high-dose antibiotics)
- Urinary tract infection or diseases causing abnormal urinary protein levels (e.g., nephrotic syndrome)
- Any other condition unsuitable for enrollment as decided by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Chaoyang District, China, 100021
Actively Recruiting
Research Team
Q
Qian Liu, M.D.
CONTACT
M
Mingguang Zhang, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here